Legemiddelindustrien (LMI)Legemiddelindustrien (LMI)Legemiddelindustrien (LMI)

Press release: COVID-19 virus affecting clinical trials in Norway


As a precautionary measure, in the continuous efforts to limit the spreading of the COVID-19 virus, and to shelter patients as well as healthcare staff, external personnel are given restricted access to hospitals, which consequently affects monitoring, auditing and inspections of ongoing clinical trials.

The restrictions – which also include a temporary halt in patient recruitment for new clinical trials – are implemented at all large hospitals nation-wide and include a provisional standstill in monitoring of ongoing research, as well, consequently delaying its outcomes.

It is imperative to note, that the precautionary measures taken, are in no way related to which studies that are ongoing, which treatment that is researched, or which company that is responsible for conducting it.

Ongoing Dialogue

LMI have contacted the health authorities, requesting advice as to how our members should relate to health personnel and hospital contact, but are yet to receive any information.

LMI, Oslo Cancer Cluster and their members have introduced their own precautionary restrictions for their employees, aiming to limit the risk of spreading the virus and to allow health personnel to prioritise according to the current, extraordinary needs.

LMI and Oslo Cancer Cluster will continue to monitor the situation closely and encourage both members and non-members to report any restrictions they might receive.


Oslo Cancer Cluster is a non-profit member organization dedicated to accelerating the development of cancer treatments.

LMI is the pharmaceutical industry association in Norway and consists of Norwegian and international companies that develop, produce, sell or market pharmaceuticals in Norway.

Contact persons

Ketil Widerberg, General Manager, Oslo Cancer Cluster

kw@oslocancercluster.no, +47 915 77 990

Hege Edvardsen, senior advisor, LMI

Hege.edvardsen@lmi.no, + 47 908 68 328



About Legemiddelindustrien (LMI)

Legemiddelindustrien (LMI)
Legemiddelindustrien (LMI)
Essendrops gate 3
0301 Oslo

23 16 15 50http://www.lmi.no

Legemiddelindustrien (LMI) er bransjeforeningen for legemiddelindustrien i Norge. Norske og utenlandske legemiddelselskaper som utvikler, produserer, selger eller mar­kedsfører legemidler i Norge kan være medlem av foreningen. LMI skal være den natur­lige bransjeforeningen for både store multinasjonale selskaper og små norske grundersel­skaper som opererer på legemiddel/life science området.

De 60 medlemsbedriftene i LMI har i underkant av 4000 ansatte i Norge og representerer over 80 prosent av legemiddelomsetningen. Det omsettes legemidler i Norge for 18 milliarder kroner.

Foreningen har som formål å ivareta medlemmenes bransjemessige interesser. Gjennom gode rammebetingelser sikrer vi norske pasienter tilgang til viktige medisiner som bidrar til helse og livskvalitet i Norge.

Subscribe to releases from Legemiddelindustrien (LMI)

Subscribe to all the latest releases from Legemiddelindustrien (LMI) by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Legemiddelindustrien (LMI)

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom